MacroGenics, Inc. (MGNX) Stock Forecast
Data as of Jun 19, 2026Healthcare · Current price $4.12 (+4.02%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| May 14, 2025 | Peter Lawson | Barclays | $3.00 | -27.1% |
| Aug 7, 2024 | Stephen Willey | Stifel Nicolaus | $6.00 | +45.8% |
| Jul 31, 2024 | Silvan Tuerkcan | JMP Securities | $8.00 | +94.4% |
| Jul 31, 2024 | Mayank Mamtani | B.Riley Financial | $5.00 | +21.5% |
| Jul 29, 2024 | Peter Lawson | Barclays | $9.00 | +118.7% |
| May 23, 2024 | Kaveri Pohlman | BTIG | $9.00 | +118.7% |
| May 13, 2024 | Debjit Chattopadhyay | H.C. Wainwright | $4.00 | -2.8% |
| May 10, 2024 | Peter Lawson | Barclays | $14.00 | +240.2% |
| May 10, 2024 | Etzer Darout | BMO Capital | $8.00 | +94.4% |
| Apr 4, 2024 | Stephen Willey | Stifel Nicolaus | $29.00 | +604.7% |
| Nov 22, 2022 | Charles Zhu | Guggenheim | $12.00 | +191.6% |
| Jul 11, 2022 | Kaveri Pohlman | BTIG | $6.00 | +45.8% |
| Jun 16, 2021 | David Nierengarten | Wedbush | $32.00 | +677.6% |
Top Analysts Covering MGNX
MGNX vs Sector & Market
| Metric | MGNX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.40 |
| Analyst Count | 3 | 8 | 18 |
| Target Upside | +50.6% | +11475.0% | +16.8% |
| P/E Ratio | -2.55 | 3.93 | 35.58 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $9M | $22M | $41M | 5 |
| 2026-09-30 | $10M | $36M | $76M | 2 |
| 2026-12-31 | $9M | $32M | $68M | 2 |
| 2027-03-31 | $17M | $60M | $125M | 2 |
| 2027-06-30 | $18M | $64M | $134M | 2 |
| 2027-09-30 | $20M | $69M | $144M | 2 |
| 2027-12-31 | $21M | $74M | $155M | 2 |
| 2028-12-31 | $148M | $148M | $148M | 3 |
| 2029-12-31 | $86M | $184M | $307M | 2 |
| 2030-12-31 | $118M | $254M | $423M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-0.77 | $-0.49 | $-0.19 | 4 |
| 2026-09-30 | $-0.72 | $-0.30 | $-0.02 | 1 |
| 2026-12-31 | $-0.41 | $-0.17 | $-0.01 | 2 |
| 2027-03-31 | $-0.88 | $-0.36 | $-0.03 | 2 |
| 2027-06-30 | $-0.88 | $-0.36 | $-0.02 | 1 |
| 2027-09-30 | $-0.44 | $-0.18 | $-0.01 | 1 |
| 2027-12-31 | $-0.35 | $-0.14 | $-0.01 | 2 |
| 2028-12-31 | $-3.35 | $-1.98 | $-0.98 | 3 |
| 2029-12-31 | $-3.01 | $-1.61 | $-0.49 | 1 |
| 2030-12-31 | $-1.80 | $-0.96 | $-0.29 | 1 |
Frequently Asked Questions
What is the analyst consensus for MGNX?
The consensus among 3 analysts covering MacroGenics, Inc. (MGNX) is Buy with an average price target of $6.00.
What is the highest price target for MGNX?
The highest price target for MGNX is $32.00, set by David Nierengarten at Wedbush on 2021-06-16.
What is the lowest price target for MGNX?
The lowest price target for MGNX is $3.00, set by Peter Lawson at Barclays on 2025-05-14.
How many analysts cover MGNX?
3 analysts have issued ratings for MacroGenics, Inc. in the past 12 months.
Is MGNX a buy or sell right now?
Based on 3 analyst ratings, MGNX has a consensus rating of Buy (2.00/5) with a +50.6% upside to the consensus target of $6.00.
What are the earnings estimates for MGNX?
Analysts estimate MGNX will report EPS of $-0.49 for the period ending 2026-06-30, with revenue estimated at $22M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.